出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2022年11月
リアルワールドエビデンスソリューション市場 : コンポーネント (サービス、異種データセット、(請求、臨床、薬局、患者)、用途 (腫瘍学、心血管、神経学、免疫学)、エンドユーザー (製薬、医療技術、支払者、プロバイダー) – 2027 年までの世界予測
Real World Evidence Solutions Market by Component (Services, Disparate Data Sets, (Claims, Clinical, Pharmacy, Patient), Application (Oncology, Cardiovascular, Neurology, Immunology), End User (Pharma, Medtech, Payers, Providers) – Global Forecast to 2027
| ページ数 | 266 |
| 図表数 | 250 |
| 種別 | 英文調査報告書 |
| 価格 |
The global RWE Solutions market is projected to reach USD 2.9 Billion by 2027 from USD 1.5 Billion in 2022, at a CAGR of 15.2% during the forecast period.
Rise in the geriatric population and the subsequent increase in the prevalence of chronic diseases and support from regulatory bodies for the use of RWE solutions is driving the growth of the RWE solutions market. Given the large pool of geriatric individuals requiring health and long-term care services, the healthcare cost per person is expected to increase in many countries. Solutions such as EHR and population health management are being employed to reduce the burden on the overworked healthcare delivery systems in several countries. The significant amount of RWD that is being generated through digital health solutions is helping in better understanding clinical outcomes. As a result, the adoption of RWE solutions is increasing globally.
Pharmacy data is expected to witness the fastest growth during the forecast period
Based on component, the RWE solutions market is segmented into data sets and services. In 2021, services segment dominated the RWE solutions market owing to the availability of a large volume of healthcare data on the basis of which advanced analytics and consulting services can be offered. The data sets segment has been further segmented into disparate data sets and integrated data sets. The disparate data sets is further segmented into clinical settings data, claims data, pharmacy data, patient-powered data, and other data sets . The pharmacy data sets segment is expected to witness fastes growth rate during the forecast period owing to rising efforts to decrease medication nonadherence and the increasing adoption of e-prescribing systems.
“Drug development and approvals dominates the RWE solutions market in 2021”
Based on the application, the RWE solutions market is broadly categorized into drug development and approvals, medical device development and approvals, post-market surveillance, market access and reimbursement/coverage decision making, and clinical & regulatory decision making. The drug development and approval segment dominated the RWE solutions market owing to increasing number of clinical trials specifically in the field of oncology and cardiovascular therapeutics. The drug development and approvals segment is further sub-segmented into oncology, cardiovascular disease, neurology, immunology, and other therapeutic areas. Cardiovascular disease segment is expected to witness fastest growth rate during the forecast period owing to increasing prevalence of CVDs and growing development of cardiovascular registries.
“Pharmaceutical and medical device companies are expected to witnessing fastest growth during the forecast period”
Based on end users, the RWE solutions market is segmented into pharmaceutical & medical device companies, healthcare providers, healthcare payers, and other end users. The pharmaceutical & medical device companies segment are expected to witness the fastest growth rate through 2027. Pharmaceutical companies require data describing both the approved and medically accepted alternative uses of previously approved drugs. Increasing growth in investments on pharmaceutical and medical device R&D and growing number of approvals are driving the use of RWE solutions in this segment. Additionally, the use of RWE solutions in meeting regulatory compliances is increasing along with payer demands related to HEOR, which are also the key factors supporting the growth of RWE solutions market.
“North America leads the RWE solutions market by region”
North America accounted for the largest share of the global RWE solutions market. Majority of established players are based in North America. Furthermore, rising geriatric population is contributing to increase in chronic disease in the region, which is driving the demand for new drugs and medical devices, thereby catering to an increasing demand for evidence generation during clinical trials and post-market surveillance activities. The Asia Pacific market is projected to register the highest CAGR during the forecast period. Market growth in the Asia Pacific is attributed to the increasing government initiatives for the adoption of RWE studies.
The break-down of primary participants is as mentioned below:
• By Company Type – Tier 1: 40%, Tier 2: 35%, and Tier 3: 25%
• By Designation – C-level: 35%, Director-level: 45%, and Others: 20%
• By Region – North America: 55%, Europe: 20%, Asia Pacific: 15%, Latin America: 5%, and Middle East and Africa : 5%.
Key players in the RWE Solutions Market
The key players operating in the RWE solutions market include IQVIA Holdings Inc. (US), IBM Corporation (US), OPTUM Inc. (US), Icon Plc (Ireland), Syneos Health Inc. (US), Parexel International Corporation (US).
Research Coverage:
The report analyzes the RWE Solutions market and aims at estimating the market size and future growth potential of various market segments, based on component, applications, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, solution offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
Market Penetration: Comprehensive information on the solution portfolios of the top players in the RWE solutions market. The report analyzes this market by component, application, end user, and region.
Market Development: Comprehensive information on the lucrative emerging markets, by component, application, end user, and region
Market Diversification: Exhaustive information about the solution portfolios, growing geographies, recent developments, and investments in the RWE solutions market
Competitive Assessment: In-depth assessment of market ranking, growth strategies, solution offerings, and capabilities of the leading players in the RWE solutions market
目次
1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.2.1 INCLUSIONS AND EXCLUSIONS 24
1.2.2 MARKETS COVERED 25
1.2.3 YEARS CONSIDERED FOR THE STUDY 25
1.3 CURRENCY 26
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 26
1.4 LIMITATIONS 26
1.5 STAKEHOLDERS 26
1.6 SUMMARY OF CHANGES 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH DATA 28
FIGURE 1 RESEARCH DESIGN 28
2.1.1 SECONDARY DATA 28
2.1.1.1 Key data from secondary sources 29
2.1.2 PRIMARY DATA 30
FIGURE 2 PRIMARY SOURCES 30
2.1.2.1 Key data from primary sources 31
2.1.2.2 Insights from primary experts 32
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 32
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 33
2.2 MARKET SIZE ESTIMATION: RWE SOLUTIONS MARKET 33
FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 34
FIGURE 6 MARKET SIZE ESTIMATION: SEGMENTAL EXTRAPOLATION 35
FIGURE 7 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 36
FIGURE 8 CAGR PROJECTIONS: OVERALL RWE SOLUTIONS MARKET 36
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 38
FIGURE 9 DATA TRIANGULATION METHODOLOGY 38
2.4 MARKET RANKING ANALYSIS 39
2.5 ASSUMPTIONS FOR THE STUDY 39
2.6 RISK ASSESSMENT 39
TABLE 2 RISK ASSESSMENT: RWE SOLUTIONS MARKET 39
2.7 LIMITATIONS 40
2.7.1 METHODOLOGY-RELATED LIMITATIONS 40
3 EXECUTIVE SUMMARY 41
FIGURE 10 RWE SOLUTIONS MARKET, BY COMPONENT, 2022 VS. 2027 (USD MILLION) 41
FIGURE 11 DATA SETS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 42
FIGURE 12 DISPARATE DATA SETS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 42
FIGURE 13 RWE SOLUTIONS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 43
FIGURE 14 RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 43
FIGURE 15 RWE SOLUTIONS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 44
FIGURE 16 RWE SOLUTIONS MARKET: GEOGRAPHIC SNAPSHOT 45
4 PREMIUM INSIGHTS 46
4.1 RWE SOLUTIONS MARKET OVERVIEW 46
FIGURE 17 SUPPORT FROM REGULATORY BODIES FOR THE USE OF RWE SOLUTIONS IS A MAJOR FACTOR DRIVING THE MARKET GROWTH 46
4.2 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY END USER AND COUNTRY (2021) 47
FIGURE 18 JAPAN ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 47
4.3 RWE SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 48
FIGURE 19 CHINA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 48
4.4 REGIONAL MIX: RWE SOLUTIONS MARKET (2022−2027) 49
FIGURE 20 NORTH AMERICA WILL CONTINUE TO DOMINATE THE RWE SOLUTIONS MARKET DURING THE FORECAST PERIOD 49
4.5 RWE SOLUTIONS MARKET: DEVELOPED VS. EMERGING MARKETS 49
FIGURE 21 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES DURING THE FORECAST PERIOD 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS 50
FIGURE 22 RWE SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
TABLE 3 MARKET DYNAMICS: IMPACT ANALYSIS 51
5.2.1 DRIVERS 51
5.2.1.1 Rise in the geriatric population and the subsequent increase in the prevalence of chronic diseases 51
5.2.1.2 Shift from volume- to value-based care 52
5.2.1.3 Potential of RWE in reducing drug development costs and expediting the drug development process 53
5.2.1.4 Increased R&D spending for the development of new pharmaceutical products and medical devices 53
FIGURE 23 NUMBER OF CLINICAL TRIALS STARTED DURING 2015–2020 54
5.2.1.5 Support from regulatory bodies for the use of RWE solutions 54
5.2.2 RESTRAINTS 55
5.2.2.1 Reluctance of medical practitioners and researchers to rely on real-world studies 55
5.2.3 OPPORTUNITIES 55
5.2.3.1 Growth opportunities in emerging markets 55
5.2.3.2 Rise in focus on end-to-end RWE services 57
5.2.4 CHALLENGES 57
5.2.4.1 Lack of universally accepted methodology standards and data processing infrastructure 57
5.2.4.2 Shortage of skilled professionals 57
6 INDUSTRY INSIGHTS 59
6.1 INDUSTRY TRENDS 59
6.1.1 EMERGING ROLE OF WEARABLE DEVICES 59
FIGURE 24 UTILIZATION OF WEARABLES IN CLINICAL TRIALS, BY THERAPEUTIC AREA, 2019 59
6.1.2 SOCIAL MEDIA-SOURCED RWE 60
6.1.3 RISE IN THE USE OF RWD AND RWE ACROSS THE PHARMACEUTICAL INDUSTRY 61
FIGURE 25 RECOMMENDED INVESTMENT MODEL FOR RWD AND RWE 61
6.1.4 INTERNAL VS. OUTSOURCED RWE ANALYTICS APPROACH 62
FIGURE 26 INTERNAL VS. OUTSOURCED RWE ANALYTICS APPROACH 62
6.1.5 INCORPORATION OF ARTIFICIAL INTELLIGENCE IN RWD MANAGEMENT 62
6.2 REAL-WORLD DATA SOURCES 63
TABLE 4 INDICATIVE LIST OF NATIONAL DATABASES IN DEVELOPED COUNTRIES 63
6.3 ECOSYSTEM ANALYSIS 64
FIGURE 27 ECOSYSTEM COVERAGE: PARENT MARKET (HEALTHCARE IT SOLUTIONS) 65
FIGURE 28 ECOSYSTEM COVERAGE: RWE SOLUTIONS MARKET 65
6.4 PORTER’S FIVE FORCES ANALYSIS 66
TABLE 5 PORTER’S FIVE FORCES ANALYSIS 66
6.4.1 THREAT OF NEW ENTRANTS 66
6.4.2 BARGAINING POWER OF SUPPLIERS 66
6.4.3 BARGAINING POWER OF BUYERS 66
6.4.4 THREAT OF SUBSTITUTES 67
6.4.5 INTENSITY OF COMPETITIVE RIVALRY 67
6.5 PRICING ANALYSIS 67
6.5.1 AVERAGE SELLING PRICE 67
6.5.2 HCIT EXPENDITURE/PRICING ANALYSIS 68
6.5.2.1 North America 68
TABLE 6 NORTH AMERICA: HEALTHCARE EXPENDITURE, BY COUNTRY 68
6.5.2.2 Europe 68
6.5.2.3 Asia Pacific 69
TABLE 7 JAPAN: HEALTHCARE IT INITIATIVES AND FUNDING 69
6.6 TECHNOLOGY ANALYSIS 70
6.7 REGULATORY BODIES, GOVERNMENTS, AND OTHER ORGANIZATIONS 70
6.7.1 NORTH AMERICA 70
6.7.1.1 Case examples 72
6.7.2 EUROPE 73
6.7.3 ASIA PACIFIC 74
6.7.3.1 China 74
6.7.3.2 Japan 74
6.8 PATENT ANALYSIS 75
6.8.1 PATENT PUBLICATION TRENDS FOR RWE SOLUTIONS 75
FIGURE 29 GLOBAL PATENT PUBLICATION TRENDS IN THE RWE SOLUTIONS MARKET, 2016–2021 75
6.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS 75
FIGURE 30 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR MEDICAL SIMULATION PATENTS (JANUARY 2011 TO JUNE 2021) 76
6.8.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE RWE SOLUTIONS MARKET 76
FIGURE 31 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR RWE SOLUTIONS, 2016–2021 76
TABLE 8 LIST OF PATENTS IN THE RWE SOLUTIONS MARKET, 2019–2022 77
6.9 KEY CONFERENCES AND EVENTS (2022-2023) 78
TABLE 9 RWE SOLUTIONS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 78
6.10 KEY STAKEHOLDERS AND BUYING CRITERIA 79
6.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 79
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS 79
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 APPLICATIONS 80
6.10.2 BUYING CRITERIA 80
FIGURE 33 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS 80
TABLE 11 KEY BUYING CRITERIA FOR TOP 3 END USERS 80
7 RWE SOLUTIONS MARKET, BY COMPONENT 81
7.1 INTRODUCTION 82
TABLE 12 RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 82
7.2 SERVICES 82
7.2.1 RISING NEED TO CONVERT DATA INTO ACTIONABLE EVIDENCE TO DRIVE DEMAND 82
TABLE 13 RWE SERVICES OFFERED BY KEY MARKET PLAYERS 83
TABLE 14 RWE SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 83
7.3 DATA SETS 84
TABLE 15 DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 84
TABLE 16 DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 85
7.3.1 DISPARATE DATA SETS 85
TABLE 17 DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 86
TABLE 18 DISPARATE DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
7.3.1.1 Clinical settings data set 87
7.3.1.1.1 Increasing utilization of EHR data for trial recruitment to fuel growth 87
FIGURE 34 ADOPTION OF EHR BY HOSPITAL SERVICE TYPE, 2019-2021 87
TABLE 19 CLINICAL SETTINGS DATA SETS OFFERED BY KEY MARKET PLAYERS 88
TABLE 20 CLINICAL SETTINGS DISPARATE DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 88
7.3.1.2 Claims data set 89
7.3.1.2.1 Growing need to understand the economic benefits of drug reimbursement by payers to drive growth 89
TABLE 21 CLAIMS DATA SETS OFFERED BY KEY MARKET PLAYERS 89
TABLE 22 CLAIMS DISPARATE DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 90
7.3.1.3 Pharmacy data set 90
7.3.1.3.1 Increasing adoption of e-prescribing systems to drive growth 90
FIGURE 35 TOTAL E-PRESCRIPTIONS AND CONTROLLED SUBSTANCE PRESCRIPTIONS IN THE US (2018-2021) 91
TABLE 23 PHARMACY DATA SETS OFFERED BY KEY MARKET PLAYERS 91
TABLE 24 PHARMACY DISPARATE DATA SET MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92
7.3.1.4 Patient-powered data set 92
7.3.1.4.1 Increasing need to access opinions on diseases and treatments across social media to drive growth 92
TABLE 25 PATIENT-POWERED DATA SETS OFFERED BY KEY MARKET PLAYERS 93
TABLE 26 RWE PATIENT-POWERED DISPARATE DATA MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 93
7.3.1.5 Registry-based data sets 94
7.3.1.5.1 Increasing number of disease registries is driving the demand for registry-based data sets in evidence generation 94
TABLE 27 USE OF REGISTRIES FOR EVIDENCE GENERATION 94
TABLE 28 REGISTRY-BASED DATA SETS OFFERED BY KEY MARKET PLAYERS 95
TABLE 29 REGISTRY-BASED DISPARATE DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 95
7.3.2 INTEGRATED DATA SETS 96
7.3.2.1 Increasing demand for integrated data from multiple sources to drive growth 96
TABLE 30 INTEGRATED DATA SETS OFFERED BY KEY MARKET PLAYERS 96
TABLE 31 INTEGRATED DATA SETS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 97
8 RWE SOLUTIONS MARKET, BY APPLICATION 98
8.1 INTRODUCTION 99
FIGURE 36 NUMBER OF CLINICAL TRIALS (COMPLETED), BY CONDITION/DISEASE, SEPTEMBER 2022 99
TABLE 32 RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 99
8.2 DRUG DEVELOPMENT AND APPROVALS 100
TABLE 33 RWE SOLUTIONS MARKET IN DRUG DEVELOPMENT AND APPROVALS, BY TYPE 2020–2027 (USD MILLION) 100
8.2.1 ONCOLOGY 100
8.2.1.1 Growing number of clinical trials focused on cancer treatment to drive growth 100
TABLE 34 LIST OF PIPELINE DRUGS FOR ONCOLOGY (2018) 101
TABLE 35 DRUG DEVELOPMENT AND APPROVALS MARKET IN ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 102
8.2.2 CARDIOVASCULAR DISEASE 102
8.2.2.1 High prevalence of CVD to drive growth 102
TABLE 36 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASE (BY FEBRUARY 2022) 103
TABLE 37 DRUG DEVELOPMENT AND APPROVALS MARKET IN CARDIOVASCULAR DISEASE, BY COUNTRY, 2020–2027 (USD MILLION) 104
8.2.3 NEUROLOGY 104
8.2.3.1 Growing prevalence of neurological disorders to drive growth 104
TABLE 38 DRUG DEVELOPMENT AND APPROVALS MARKET IN NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 105
8.2.4 IMMUNOLOGY 105
8.2.4.1 Increasing focus on developing innovative products to drive growth 105
TABLE 39 DRUG DEVELOPMENT AND APPROVALS MARKET IN IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 106
8.2.5 OTHER THERAPEUTIC AREAS 106
TABLE 40 DRUG DEVELOPMENT AND APPROVALS MARKET IN OTHER THERAPEUTIC AREAS, BY COUNTRY, 2020–2027 (USD MILLION) 107
8.3 MEDICAL DEVICE DEVELOPMENT AND APPROVALS 107
8.3.1 INCREASING RESEARCH IN MEDICAL DEVICE DEVELOPMENT TO DRIVE DEMAND 107
TABLE 41 RWE SOLUTIONS MARKET IN MEDICAL DEVICE DEVELOPMENT AND APPROVALS, BY COUNTRY, 2020–2027 (USD MILLION) 108
8.4 POST-MARKET SURVEILLANCE 109
8.4.1 EMR AND PRODUCT/PATIENT REGISTRIES HAVE BECOME KEY DATA SOURCES FOR GENERATING EVIDENCE IN POST-MARKET SURVEILLANCE 109
TABLE 42 RWE SOLUTIONS MARKET IN POST-MARKET SURVEILLANCE, BY COUNTRY, 2020–2027 (USD MILLION) 110
8.5 MARKET ACCESS AND REIMBURSEMENT/COVERAGE DECISION MAKING 110
8.5.1 GROWING USE OF RWE SOLUTIONS TO DEVELOP ECONOMIC AND BUDGET IMPACT MODELS 110
TABLE 43 RWE SOLUTIONS MARKET IN MARKET ACCESS AND REIMBURSEMENT/COVERAGE DECISION MAKING, BY COUNTRY, 2020–2027 (USD MILLION) 111
8.6 CLINICAL AND REGULATORY DECISION MAKING 111
8.6.1 LIMITED VALIDITY OF RANDOMIZED CONTROLLED TRIALS DRIVING THE USE OF RWE SOLUTIONS IN THE SEGMENT 111
TABLE 44 RWE SOLUTIONS MARKET IN CLINICAL AND REGULATORY DECISION MAKING, BY COUNTRY, 2020–2027 (USD MILLION) 112
9 RWE SOLUTIONS MARKET, BY END USER 113
9.1 INTRODUCTION 114
TABLE 45 RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 114
9.2 PHARMACEUTICAL & MEDICAL DEVICE COMPANIES 114
9.2.1 INCREASED R&D EXPENDITURE IN INNOVATIVE MEDICINES TO DRIVE MARKET GROWTH 114
FIGURE 37 FDA PHASE TRANSITION SUCCESS RATES, 2011–2020 115
FIGURE 38 ANNUAL DRUG APPROVALS BY CDER (FDA), 2011–2021 116
FIGURE 39 R&D SPENDING OF PHARMA MEMBER COMPANIES, 2011–2020 116
TABLE 46 RWE SOLUTIONS MARKET FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 117
9.3 HEALTHCARE PAYERS 117
9.3.1 INCREASED FOCUS ON OUTCOME-BASED PAYMENT MODELS TO DRIVE DEMAND 117
TABLE 47 RWE SOLUTIONS MARKET FOR HEALTHCARE PAYERS, BY COUNTRY, 2020–2027 (USD MILLION) 118
9.4 HEALTHCARE PROVIDERS 119
9.4.1 RISE IN THE NEED TO IMPROVE THE PROFITABILITY OF HEALTHCARE PROVIDERS TO BOOST USE 119
TABLE 48 RWE SOLUTIONS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2020–2027 (USD MILLION) 120
9.5 OTHER END USERS 120
TABLE 49 RWE SOLUTIONS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 121
10 RWE SOLUTIONS MARKET, BY REGION 122
10.1 INTRODUCTION 123
TABLE 50 RWE SOLUTIONS MARKET, BY REGION, 2020–2027 (USD MILLION) 123
10.2 NORTH AMERICA 123
FIGURE 40 NORTH AMERICA: RWE SOLUTIONS MARKET SNAPSHOT 124
TABLE 51 NORTH AMERICA: RWE SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 124
TABLE 52 NORTH AMERICA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 125
TABLE 53 NORTH AMERICA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 54 NORTH AMERICA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 55 NORTH AMERICA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 126
TABLE 56 NORTH AMERICA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 126
TABLE 57 NORTH AMERICA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 127
10.2.1 US 127
10.2.1.1 The US accounted for the largest share of the North American market 127
TABLE 58 US: MACROECONOMIC INDICATORS 128
TABLE 59 US: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 128
TABLE 60 US: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 61 US: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 129
TABLE 62 US: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 129
TABLE 63 US: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 64 US: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 130
10.2.2 CANADA 130
10.2.2.1 Growing number of clinical trials in Canada to drive market growth 130
TABLE 65 CANADA: MACROECONOMIC INDICATORS 131
TABLE 66 CANADA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 131
TABLE 67 CANADA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 68 CANADA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 69 CANADA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 132
TABLE 70 CANADA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 133
TABLE 71 CANADA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 133
10.3 EUROPE 133
TABLE 72 EUROPE: RWE SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 134
TABLE 73 EUROPE: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 135
TABLE 74 EUROPE: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 135
TABLE 75 EUROPE: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 135
TABLE 76 EUROPE: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 136
TABLE 77 EUROPE: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 78 EUROPE: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 137
10.3.1 GERMANY 137
10.3.1.1 High pharmaceutical R&D spending in Germany to boost the market growth 137
TABLE 79 GERMANY: MACROECONOMIC INDICATORS 138
TABLE 80 GERMANY: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 138
TABLE 81 GERMANY: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 82 GERMANY: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 83 GERMANY: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 140
TABLE 84 GERMANY: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 140
TABLE 85 GERMANY: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 141
10.3.2 UK 141
10.3.2.1 The growing adoption of HTA in the UK supports market growth 141
TABLE 86 UK: MACROECONOMIC INDICATORS 142
TABLE 87 UK: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 142
TABLE 88 UK: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 89 UK: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 90 UK: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 143
TABLE 91 UK: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 144
TABLE 92 UK: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 144
10.3.3 FRANCE 144
10.3.3.1 High number of oncology clinical trials in France to drive market growth 144
TABLE 93 FRANCE: MACROECONOMIC INDICATORS 145
TABLE 94 FRANCE: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 145
TABLE 95 FRANCE: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 96 FRANCE: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 97 FRANCE: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 146
TABLE 98 FRANCE: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 147
TABLE 99 FRANCE: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 147
10.3.4 ITALY 147
10.3.4.1 The demand for RWE in Italy is high due to the widespread use of pay-for-outcomes 147
TABLE 100 ITALY: MACROECONOMIC INDICATORS 148
TABLE 101 ITALY: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 149
TABLE 102 ITALY: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 149
TABLE 103 ITALY: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 149
TABLE 104 ITALY: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 105 ITALY: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 150
TABLE 106 ITALY: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 151
10.3.5 SPAIN 151
10.3.5.1 Rising R&D expenditure to propel market growth in Spain 151
TABLE 107 SPAIN: MACROECONOMIC INDICATORS 152
TABLE 108 SPAIN: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 152
TABLE 109 SPAIN: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 152
TABLE 110 SPAIN: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 153
TABLE 111 SPAIN: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 153
TABLE 112 SPAIN: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 154
TABLE 113 SPAIN: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 154
10.3.6 REST OF EUROPE 154
TABLE 114 REST OF EUROPE: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 155
TABLE 115 REST OF EUROPE: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 116 REST OF EUROPE: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 156
TABLE 117 REST OF EUROPE: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 156
TABLE 118 REST OF EUROPE: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 157
TABLE 119 REST OF EUROPE: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 157
10.4 ASIA PACIFIC 158
FIGURE 41 ASIA PACIFIC: RWE SOLUTIONS MARKET SNAPSHOT 158
TABLE 120 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 159
TABLE 121 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 159
TABLE 122 ASIA PACIFIC: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 123 ASIA PACIFIC: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 160
TABLE 124 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 160
TABLE 125 ASIA PACIFIC: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 161
TABLE 126 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 161
10.4.1 JAPAN 161
10.4.1.1 Stringent regulatory scenario in Japan to restrain market growth 161
TABLE 127 JAPAN: MACROECONOMIC INDICATORS 162
TABLE 128 JAPAN: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 163
TABLE 129 JAPAN: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 163
TABLE 130 JAPAN: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 163
TABLE 131 JAPAN: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 164
TABLE 132 JAPAN: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 164
TABLE 133 JAPAN: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 165
10.4.2 CHINA 165
10.4.2.1 Low cost of clinical trials and large pharmaceutical R&D base in China to drive market growth 165
TABLE 134 CHINA: MACROECONOMIC INDICATORS 166
TABLE 135 CHINA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 166
TABLE 136 CHINA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 167
TABLE 137 CHINA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 167
TABLE 138 CHINA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 167
TABLE 139 CHINA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 168
TABLE 140 CHINA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 168
10.4.3 INDIA 168
10.4.3.1 Growing adoption of outcomes-based research among pharmaceutical and medical device manufacturers in India to drive market growth 168
TABLE 141 INDIA: MACROECONOMIC INDICATORS 169
TABLE 142 INDIA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 169
TABLE 143 INDIA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 170
TABLE 144 INDIA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 170
TABLE 145 INDIA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 170
TABLE 146 INDIA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 147 INDIA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 171
10.4.4 REST OF ASIA PACIFIC 171
TABLE 148 REST OF ASIA PACIFIC: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 172
TABLE 149 REST OF ASIA PACIFIC: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 150 REST OF ASIA PACIFIC: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 173
TABLE 151 REST OF ASIA PACIFIC: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 173
TABLE 152 REST OF ASIA PACIFIC: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 153 REST OF ASIA PACIFIC: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 174
10.5 LATIN AMERICA 174
10.5.1 INCREASED HEALTHCARE EXPENDITURE TO SUPPORT MARKET GROWTH 174
TABLE 154 LATIN AMERICA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 175
TABLE 155 LATIN AMERICA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 175
TABLE 156 LATIN AMERICA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 157 LATIN AMERICA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 176
TABLE 158 LATIN AMERICA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 177
TABLE 159 LATIN AMERICA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 177
10.6 MIDDLE EAST & AFRICA 177
10.6.1 GROWING AVAILABILITY OF HEALTHCARE FUNDING IN THE MIDDLE EAST OFFERS OPPORTUNITIES FOR MARKET GROWTH 177
TABLE 160 MIDDLES EAST & AFRICA: RWE SOLUTIONS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 178
TABLE 161 MIDDLES EAST & AFRICA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 178
TABLE 162 MIDDLES EAST & AFRICA: DISPARATE DATA SETS MARKET, BY TYPE, 2020–2027 (USD MILLION) 179
TABLE 163 MIDDLES EAST & AFRICA: RWE SOLUTIONS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 179
TABLE 164 MIDDLES EAST & AFRICA: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 180
TABLE 165 MIDDLES EAST & AFRICA: RWE SOLUTIONS MARKET, BY END USER, 2020–2027 (USD MILLION) 180
11 COMPETITIVE LANDSCAPE 181
11.1 OVERVIEW 181
11.2 STRATEGIES ADOPTED BY KEY PLAYERS /RIGHT TO WIN 181
TABLE 166 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE RWE SOLUTIONS MARKET 182
11.3 REVENUE SHARE ANALYSIS OF KEY PLAYERS 184
FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN THE RWE SOLUTIONS MARKET 184
11.4 MARKET RANKING ANALYSIS 185
FIGURE 43 RWE SOLUTIONS MARKET RANKING, BY KEY PLAYER, 2021 185
11.5 COMPETITIVE BENCHMARKING 186
TABLE 167 RWE SOLUTIONS MARKET: DETAILED LIST OF SMALL & MEDIUM PLAYERS 186
11.6 COMPANY FOOTPRINT 187
11.6.1 END-USER FOOTPRINT OF COMPANIES 187
11.6.2 PRODUCT FOOTPRINT OF COMPANIES 188
11.6.3 REGIONAL FOOTPRINT OF COMPANIES 189
11.7 COMPANY EVALUATION QUADRANT 190
11.7.1 STARS 191
11.7.2 EMERGING LEADERS 191
11.7.3 PERVASIVE PLAYERS 191
11.7.4 PARTICIPANTS 191
FIGURE 44 RWE SOLUTIONS MARKET: COMPANY EVALUATION QUADRANT (2021) 192
11.8 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES 192
11.8.1 PROGRESSIVE COMPANIES 192
11.8.2 STARTING BLOCKS 193
11.8.3 RESPONSIVE COMPANIES 193
11.8.4 DYNAMIC COMPANIES 193
FIGURE 45 START-UP/SME EVALUATION QUADRANT (2021) 194
11.9 COMPETITIVE SCENARIO 194
11.9.1 FDA APPROVALS/SERVICE ENHANCEMENTS 194
TABLE 168 FDA APPROVALS/ENHANCEMENTS, 2019–2022 195
11.9.2 DEALS 195
TABLE 169 DEALS, 2019–2022 195
11.9.3 OTHER DEVELOPMENTS 197
TABLE 170 OTHER DEVELOPMENTS, 2019–2022 197
12 COMPANY PROFILES 198
12.1 KEY PLAYERS 198
(Business Overview, Products, Recent Developments, MnM View)*
12.1.1 IQVIA HOLDINGS INC. 198
TABLE 171 IQVIA HOLDINGS INC.: BUSINESS OVERVIEW 198
FIGURE 46 IQVIA HOLDINGS INC: COMPANY SNAPSHOT (2021) 199
12.1.2 IBM CORPORATION (IBM) 202
TABLE 172 IBM CORPORATION: BUSINESS OVERVIEW 202
FIGURE 47 IBM CORPORATION: COMPANY SNAPSHOT (2021) 203
12.1.3 OPTUM INC. (A SUBSIDIARY OF THE UNITED HEALTH GROUP, INC.) 205
TABLE 173 OPTUM INC.: BUSINESS OVERVIEW 205
FIGURE 48 OPTUM INC.: COMPANY SNAPSHOT (2021) 206
12.1.4 ICON PLC. 208
TABLE 174 ICON PLC.: BUSINESS OVERVIEW 208
FIGURE 49 ICON PLC.: COMPANY SNAPSHOT (2021) 209
12.1.5 SYNEOS HEALTH, INC. 211
TABLE 175 SYNEOS HEALTH INC.: BUSINESS OVERVIEW 211
FIGURE 50 SYNEOS HEALTH INC.: COMPANY SNAPSHOT (2021) 212
12.1.6 PAREXEL INTERNATIONAL CORPORATION 214
TABLE 176 PAREXEL INTERNATIONAL CORPORATION: BUSINESS OVERVIEW 214
12.1.7 THERMO FISHER SCIENTIFIC INC. 216
TABLE 177 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 216
FIGURE 51 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) 217
12.1.8 LABCORP HOLDINGS 219
TABLE 178 LABCORP HOLDINGS: BUSINESS OVERVIEW 219
FIGURE 52 LABCORP HOLDINGS: COMPANY SNAPSHOT (2021) 220
12.1.9 ORACLE CORPORATION 222
TABLE 179 ORACLE CORPORATION: BUSINESS OVERVIEW 222
FIGURE 53 ORACLE CORPORATION: COMPANY SNAPSHOT (2021) 223
12.1.10 ELEVANCE HEALTH 225
TABLE 180 ELEVANCE HEALTH: BUSINESS OVERVIEW 225
FIGURE 54 ELEVANCE HEALTH: COMPANY SNAPSHOT (2021) 226
12.1.11 SAS INSTITUTE 228
TABLE 181 SAS INSTITUTE: BUSINESS OVERVIEW 228
FIGURE 55 SAS INSTITUTE: COMPANY SNAPSHOT (2021) 229
12.1.12 AETION INC. 231
TABLE 182 AETION INC.: BUSINESS OVERVIEW 231
12.1.13 TRINETX LLC 234
TABLE 183 TRINETX LLC: BUSINESS OVERVIEW 234
12.1.14 TRINITY LIFE SCIENCES 237
TABLE 184 TRINITY LIFE SCIENCES: BUSINESS OVERVIEW 237
12.1.15 PERKINELMER INC. 239
TABLE 185 PERKINELMER INC.: BUSINESS OVERVIEW 239
FIGURE 56 PERKINELMER INC.: COMPANY SNAPSHOT (2021) 240
12.1.16 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION 242
TABLE 186 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: BUSINESS OVERVIEW 242
FIGURE 57 COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: COMPANY SNAPSHOT (2021) 243
12.1.17 CLINIGEN 245
TABLE 187 CLINIGEN: BUSINESS OVERVIEW 245
FIGURE 58 CLINIGEN: COMPANY SNAPSHOT (2021) 245
12.1.18 CEGEDIM HEALTH DATA 247
TABLE 188 CEGEDIM HEALTH DATA: BUSINESS OVERVIEW 247
FIGURE 59 CEGEDIM HEALTH DATA: COMPANY SNAPSHOT (2021) 247
12.1.19 VERANTOS INC. 249
TABLE 189 VERANTOS INC.: BUSINESS OVERVIEW 249
12.1.20 MEDPACE HOLDINGS INC. 251
TABLE 190 MEDPACE HOLDINGS INC.: BUSINESS OVERVIEW 251
FIGURE 60 MEDPCE HOLDINGS INC.: COMPANY SNAPSHOT (2021) 252
*Details on Business Overview, Products, Recent Developments, MnM View might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 254
12.2.1 HEALTHVERITY INC. 254
12.2.2 DATAVANT 254
12.2.3 SYAPSE INC. 255
12.2.4 TEMPUS LABS INC. 255
12.2.5 FLATIRON HEALTH 256
13 APPENDIX 257
13.1 DISCUSSION GUIDE 257
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 262
13.3 CUSTOMIZATION OPTIONS 264
13.4 RELATED REPORTS 264
13.5 AUTHOR DETAILS 265